Immunomedics (IMMU) Stock: Heads Up On Regulatory Update

Immunomedics, Inc. (NASDAQ: IMMU) is having a relatively strong start to the trading session this morning, and for good reason. The company announced that the FDA has accepted its Biologics License Agreement, leading to excitement among investors and sending the stock screaming for the top. Today, we’ll talk about: The acceptance of the Biologics License … Read more

Immunomedics (IMMU) Stock: Headed For The Top On Update

Immunomedics, Inc. (NASDAQ: IMMU) is having a great start to the trading session this morning, and for good reason. The company provided a comprehensive overview of clinical development at the 2018 ASCO Annual Meeting. Of course, the news led to excitement among investors, sending the stock screaming for the top. Today, we’ll talk about: The … Read more

Immunomedics (IMMU) Stock: Judge Halts Licensing Deal With SGEN

Immunomedics, Inc. (NASDAQ: IMMU) Immunomedics was having a relatively normal day in the market today. After starting the day in the green, the stock dipped a bit, then traded on the day relatively flat. While there was some movement, it definitely wasn’t worth writing home about. That is, until minutes ago when the stock spiked … Read more

Immunomedics (IMMU) Stock: Gaining On Seattle Genetics (SGEN) Deal

Immunomedics, Inc. (NASDAQ: IMMU) Immunomedics is having an incredibly strong day in the market today. In fact, when the market opened, the stock was already trading well into the green. However, since then, there has been no signs of slowing gains as the stock continues to rocket upward. Below, we’ll talk about what we’re seeing … Read more

Today In Biotech: MannKind (MNKD), Nanosphere (NSPH), Gilead Sciences (GILD), Immunomedics (IMMU)

MannKind Corporation Is Up: Is There Room Left For More Gains? MannKind Corporation (NASDAQ: MNKD) MannKind is having an incredible day in the market today. As market turmoil starts to subside, the stock is climbing; currently it’s (2:15) trading at $4.00 per share after a gain of 3.09% so far. While we’re likely to see … Read more